Cargando…
Epitope Mapping: The First Step in Developing Epitope-Based Vaccines
Antibodies are an effective line of defense in preventing infectious diseases. Highly potent neutralizing antibodies can intercept a virus before it attaches to its target cell and, thus, inactivate it. This ability is based on the antibodies’ specific recognition of epitopes, the sites of the antig...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7100438/ https://www.ncbi.nlm.nih.gov/pubmed/17516710 http://dx.doi.org/10.2165/00063030-200721030-00002 |
_version_ | 1783511441349804032 |
---|---|
author | Gershoni, Jonathan M. Roitburd-Berman, Anna Siman-Tov, Dror D. Freund, Natalia Tarnovitski Weiss, Yael |
author_facet | Gershoni, Jonathan M. Roitburd-Berman, Anna Siman-Tov, Dror D. Freund, Natalia Tarnovitski Weiss, Yael |
author_sort | Gershoni, Jonathan M. |
collection | PubMed |
description | Antibodies are an effective line of defense in preventing infectious diseases. Highly potent neutralizing antibodies can intercept a virus before it attaches to its target cell and, thus, inactivate it. This ability is based on the antibodies’ specific recognition of epitopes, the sites of the antigen to which antibodies bind. Thus, understanding the antibody/epitope interaction provides a basis for the rational design of preventive vaccines. It is assumed that immunization with the precise epitope, corresponding to an effective neutralizing antibody, would elicit the generation of similarly potent antibodies in the vaccinee. Such a vaccine would be a ‘B-cell epitope-based vaccine’, the implementation of which requires the ability to backtrack from a desired antibody to its corresponding epitope. In this article we discuss a range of methods that enable epitope discovery based on a specific antibody. Such a reversed immunological approach is the first step in the rational design of an epitope-based vaccine. Undoubtedly, the gold standard for epitope definition is x-ray analyses of crystals of antigen: antibody complexes. This method provides atomic resolution of the epitope; however, it is not readily applicable to many antigens and antibodies, and requires a very high degree of sophistication and expertise. Most other methods rely on the ability to monitor the binding of the antibody to antigen fragments or mutated variations. In mutagenesis of the antigen, loss of binding due to point modification of an amino acid residue is often considered an indication of an epitope component. In addition, computational combinatorial methods for epitope mapping are also useful. These methods rely on the ability of the antibody of interest to affinity isolate specific short peptides from combinatorial phage display peptide libraries. The peptides are then regarded as leads for the definition of the epitope corresponding to the antibody used to screen the peptide library. For epitope mapping, computational algorithms have been developed, such as Mapitope, which has recently been found to be effective in mapping conformational discontinuous epitopes. The pros and cons of various approaches towards epitope mapping are also discussed. |
format | Online Article Text |
id | pubmed-7100438 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-71004382020-03-27 Epitope Mapping: The First Step in Developing Epitope-Based Vaccines Gershoni, Jonathan M. Roitburd-Berman, Anna Siman-Tov, Dror D. Freund, Natalia Tarnovitski Weiss, Yael BioDrugs Drug Development Antibodies are an effective line of defense in preventing infectious diseases. Highly potent neutralizing antibodies can intercept a virus before it attaches to its target cell and, thus, inactivate it. This ability is based on the antibodies’ specific recognition of epitopes, the sites of the antigen to which antibodies bind. Thus, understanding the antibody/epitope interaction provides a basis for the rational design of preventive vaccines. It is assumed that immunization with the precise epitope, corresponding to an effective neutralizing antibody, would elicit the generation of similarly potent antibodies in the vaccinee. Such a vaccine would be a ‘B-cell epitope-based vaccine’, the implementation of which requires the ability to backtrack from a desired antibody to its corresponding epitope. In this article we discuss a range of methods that enable epitope discovery based on a specific antibody. Such a reversed immunological approach is the first step in the rational design of an epitope-based vaccine. Undoubtedly, the gold standard for epitope definition is x-ray analyses of crystals of antigen: antibody complexes. This method provides atomic resolution of the epitope; however, it is not readily applicable to many antigens and antibodies, and requires a very high degree of sophistication and expertise. Most other methods rely on the ability to monitor the binding of the antibody to antigen fragments or mutated variations. In mutagenesis of the antigen, loss of binding due to point modification of an amino acid residue is often considered an indication of an epitope component. In addition, computational combinatorial methods for epitope mapping are also useful. These methods rely on the ability of the antibody of interest to affinity isolate specific short peptides from combinatorial phage display peptide libraries. The peptides are then regarded as leads for the definition of the epitope corresponding to the antibody used to screen the peptide library. For epitope mapping, computational algorithms have been developed, such as Mapitope, which has recently been found to be effective in mapping conformational discontinuous epitopes. The pros and cons of various approaches towards epitope mapping are also discussed. Springer International Publishing 2012-08-15 2007 /pmc/articles/PMC7100438/ /pubmed/17516710 http://dx.doi.org/10.2165/00063030-200721030-00002 Text en © Adis Data Information BV 2007 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Drug Development Gershoni, Jonathan M. Roitburd-Berman, Anna Siman-Tov, Dror D. Freund, Natalia Tarnovitski Weiss, Yael Epitope Mapping: The First Step in Developing Epitope-Based Vaccines |
title | Epitope Mapping: The First Step in Developing Epitope-Based Vaccines |
title_full | Epitope Mapping: The First Step in Developing Epitope-Based Vaccines |
title_fullStr | Epitope Mapping: The First Step in Developing Epitope-Based Vaccines |
title_full_unstemmed | Epitope Mapping: The First Step in Developing Epitope-Based Vaccines |
title_short | Epitope Mapping: The First Step in Developing Epitope-Based Vaccines |
title_sort | epitope mapping: the first step in developing epitope-based vaccines |
topic | Drug Development |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7100438/ https://www.ncbi.nlm.nih.gov/pubmed/17516710 http://dx.doi.org/10.2165/00063030-200721030-00002 |
work_keys_str_mv | AT gershonijonathanm epitopemappingthefirststepindevelopingepitopebasedvaccines AT roitburdbermananna epitopemappingthefirststepindevelopingepitopebasedvaccines AT simantovdrord epitopemappingthefirststepindevelopingepitopebasedvaccines AT freundnataliatarnovitski epitopemappingthefirststepindevelopingepitopebasedvaccines AT weissyael epitopemappingthefirststepindevelopingepitopebasedvaccines |